Synergism between cyclophosphamide and interleukin-2 Book Section

  


Authors: Mertelsmann, R.; Lindemann, A.; Kolitz, J. E.; Herrmann, F.
Editors: Lotzová, E.; Herberman, R. B.
Article/Chapter Title: Synergism between cyclophosphamide and interleukin-2
Abstract: In view of the therapeutic potential of interleukin-2 (IL-2) in the treatment of patients with malignant diseases, recent efforts have focused on reducing the side effects of this potentially toxic therapeutic approach as well as on the design of new treatment schedules in an effort to increase efficacy. 1 Another approach currently being explored is the search for agents which are synergistic with IL-2. Since the efficacy of IL-2-based treatments in animal models is strictly dose-dependent and since the maximum tolerated dose of IL-2 is considerably lower in man than in the most widely used animal models, it appears that IL-2 is unlikely to be used as a single agent, at least in the treatment of established tumors. © 1990 by CRC Press, Inc.
Book Title: Interleukin-2 and Killer Cells in Cancer
ISBN: 0-8493-5388-2
Publisher: CRC Press/Taylor & Francis Group  
Publication Place: Boca Raton, FL
Date Published: 1990-01-01
Start Page: 125
End Page: 132
Language: English
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85051821188&doi=10.1201%2f9781351073790&partnerID=40&md5=2674dd1edf55e470a300f18ca2adb0f3
Notes: Book Chapter: 9 -- DOI for complete book: 10.1201/9781351073790 -- Export Date: 4 September 2018 -- Source: Scopus